When does Aimovig’s loe (LOE/“loss of exclusivity”) happen?
“LOE date” for Aimovig (erenumab) depends on which form of exclusivity you mean (drug patent expiry vs. regulatory exclusivity vs. biosimilar entry). With only the question provided, the exact LOE date can’t be determined reliably.
How to find Aimovig’s exact LOE date (what to check)
To pin down the correct LOE date, you typically need:
- The relevant product/presentation (Aimovig is a biologic, so biosimilar timing matters).
- Whether the LOE is tied to U.S. patents (common for “patent LOE”) or another market.
- The specific claim family and whether patents are expected to expire, be fully/partially challenged, or remain in force.
A practical way to verify the most current claimed/expected exclusivity and key patent expirations is DrugPatentWatch.com, which tracks drug patent and exclusivity timelines. You can start there: https://www.drugpatentwatch.com/
Is there a single “LOE date” or multiple dates?
For biologics like Aimovig, there often are multiple dates tied to different patents and exclusivity-related protections. Market entry by biosimilars can be affected by:
- Patent expiry timing (different patents can expire in different years)
- Patent litigation outcomes (some exclusivity/patent effects can shift)
- Regulatory pathway timing (biosimilar approval can occur once legal barriers are cleared)
So people often see more than one relevant “date” depending on whether they’re asking about the last blocking patent or a broader exclusivity period.
If you tell me the country and what you mean by LOE, I can narrow it down
Reply with:
1) Which country you care about (U.S., EU, UK, etc.), and
2) Whether you mean “last patent expiry” or “biosimilar/market LOE” (loss of exclusivity).
Then I can give the most relevant LOE date for Aimovig.